drugset / Trial / NCT05478109

A Clinical Trial of XZP-3287 for Material Balance

NCT05478109

Phase 1 Unknown 10 enrolled Xuanzhu Biopharmaceutical Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

A single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of \[14C\] XZP-3287

Timeline

Start
2022-08-02
Primary completion
2023-01-04
Completion
2023-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject XZP-3287 Unknown 360 mg Oral

Indications

No indication recorded.